Envveno Medical CORP DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
enVVeno Medical Corporation is seeking stockholder approval for a reverse stock split to maintain its Nasdaq listing and improve stock marketability.
NASDAQ
enVVeno Medical Corporation has filed definitive additional materials for a proxy statement with the SEC.
NASDAQ
enVVeno Medical Corporation is awaiting a critical FDA decision on its VenoValve appeal by year-end 2025, while also seeking shareholder approval for a new 2025 Equity Incentive Plan and director elections.
NASDAQ
DEF 14A: enVVeno Medical Corporation Seeks Shareholder Approval for Key Initiatives at 2024 Annual Meeting
enVVeno Medical Corporation is seeking shareholder approval for the election of directors, executive compensation, and the ratification of their accounting firm at their upcoming annual meeting.